JP2008024603A - Complex powder of vitamin e and proline and method for producing the same - Google Patents
Complex powder of vitamin e and proline and method for producing the same Download PDFInfo
- Publication number
- JP2008024603A JP2008024603A JP2006195602A JP2006195602A JP2008024603A JP 2008024603 A JP2008024603 A JP 2008024603A JP 2006195602 A JP2006195602 A JP 2006195602A JP 2006195602 A JP2006195602 A JP 2006195602A JP 2008024603 A JP2008024603 A JP 2008024603A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- proline
- powder
- trade name
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 49
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 229940088594 vitamin Drugs 0.000 title 1
- 229930003231 vitamin Natural products 0.000 title 1
- 235000013343 vitamin Nutrition 0.000 title 1
- 239000011782 vitamin Substances 0.000 title 1
- 150000003722 vitamin derivatives Chemical class 0.000 title 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 166
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 79
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 79
- 229940046009 vitamin E Drugs 0.000 claims abstract description 79
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 79
- 239000011709 vitamin E Substances 0.000 claims abstract description 79
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 41
- 239000003960 organic solvent Substances 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 230000000052 comparative effect Effects 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229960000984 tocofersolan Drugs 0.000 description 7
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000002076 α-tocopherol Substances 0.000 description 6
- 235000004835 α-tocopherol Nutrition 0.000 description 6
- 244000061458 Solanum melongena Species 0.000 description 5
- 235000002597 Solanum melongena Nutrition 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009862 primary prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明は、ビタミンEとプロリンを有機溶媒中で攪拌することによって、ビタミンEとプロリンの複合体を形成させ、有機溶媒を留去、乾燥させて得られるビタミンE含量が高く、且つ、流動性の良い粉末とその製造方法に関する。 In the present invention, vitamin E and proline are stirred in an organic solvent to form a complex of vitamin E and proline, and the organic solvent is distilled off and dried to obtain a high vitamin E content and fluidity. The present invention relates to a good powder and a method for producing the same.
粘稠で油状であるビタミンEは、人を対象とした試験において、心筋梗塞のような冠状動脈疾患などの一次予防(Lancet 356:1213-1218,2000(非特許文献1))に対して、前立腺癌の予防(J Natl Cancer Inst 90:440-6,1998(非特許文献2))に対して、さらにはアルツハイマーの認識機能の衰えの抑制(Dimentia 1:134-142,1987(非特許文献3))に対して有効であると判断されている。上記以外の疾患に対しても、ビタミンE単独、あるいはビタミンCや亜鉛などと併用して摂取することによって、予防効果があるとの文献が多数ある。 Vitamin E, which is viscous and oily, is used for primary prevention of coronary artery disease such as myocardial infarction (Lancet 356: 1213-1218, 2000 (Non-Patent Document 1)) in human subjects. For prevention of prostate cancer (J Natl Cancer Inst 90: 440-6,1998 (Non-Patent Document 2)) and further suppression of decline in Alzheimer's cognitive function (Dimentia 1: 134-142,1987 (Non-Patent Document 2) 3)) is determined to be effective. There are a number of documents that have a preventive effect on diseases other than those mentioned above by ingesting vitamin E alone or in combination with vitamin C or zinc.
しかしながらビタミンEは、常温で油状であり、さらには脂溶性で粘性が極めて高いため、医薬品及び食品へ用いる際には工夫を要する。 However, vitamin E is oily at room temperature, and is fat-soluble and extremely viscous.
一例としては、ビタミンEを粉末へと形態変化させることであり、粉末にすることによって、容易に医薬品及び食品素材へ均一に混合することができ、商品へと加工する上で極めて有効な方法である。 An example is changing the form of vitamin E into powder, and by making it into powder, it can be easily mixed uniformly into pharmaceuticals and food materials, and is an extremely effective method for processing into products. is there.
ゆえに、ビタミンEを粉末にする特許が多数あり、例えば乳化剤、ゼラチン及びカゼインナトリウム等のタンパク質、アラビアガム等のガム類、単糖及び二糖等の糖類、糖アルコール、サポニン、化工澱粉及びデキストリン等の多糖類を単独あるいは複合させて用いることで乳化粉末にする特許(特開昭60−178882号公報(特許文献1)、特開昭61−60619号公報(特許文献2)、特開昭64−61417号公報(特許文献3)、特開平8−143456号公報(特許文献4)、特開平10−127258号公報(特許文献5)、特開平11−193229号公報(特許文献6)、特開2000−247869号公報(特許文献7)、特開2004−75600号公報(特許文献8))などが報告されている。 Therefore, there are many patents for powdering vitamin E, such as emulsifiers, proteins such as gelatin and sodium casein, gums such as gum arabic, saccharides such as monosaccharides and disaccharides, sugar alcohols, saponins, modified starches and dextrins, etc. Patents to make an emulsified powder by using these polysaccharides alone or in combination (Japanese Patent Application Laid-Open No. 60-178882 (Patent Document 1), Japanese Patent Application Laid-Open No. 61-60619 (Patent Document 2), Japanese Patent Application Laid-Open No. JP-A-61417 (Patent Document 3), JP-A-8-143456 (Patent Document 4), JP-A-10-127258 (Patent Document 5), JP-A-11-193229 (Patent Document 6), JP 2000-247869 (Patent Document 7), JP-A-2004-75600 (Patent Document 8)) and the like have been reported.
しかしながら乳化粉末による方法では、何れもビタミンEを高含有させた粉末とするには困難であり、さらには高含有させると粉体の流動性が非常に悪くなるという欠点を有していた。 However, any of the methods using emulsified powder has a drawback that it is difficult to obtain a powder containing a high amount of vitamin E, and further, the fluidity of the powder becomes very poor when the content is high.
本発明の課題は、常温で油状であり、脂溶性で粘性が極めて高いビタミンEを、ビタミンE含量が高く、且つ、流動性の良い粉末を見出し製造することである。 An object of the present invention is to find and produce a vitamin E that is oily at room temperature, is fat-soluble and has extremely high viscosity, and has a high vitamin E content and good fluidity.
本発明者は、上記課題を達成するために鋭意検討を重ねた結果、ビタミンEとプロリンと有機溶媒を配合し、室温乃至加熱しながら攪拌することによってビタミンEとプロリンの複合体を形成させ、有機溶媒を留去、乾燥させることで、ビタミンE含量が高く、且つ、流動性の良い粉末になることを見出し、本発明を完成するに至った。 As a result of intensive studies to achieve the above-mentioned problems, the present inventor blended vitamin E, proline and an organic solvent, and formed a complex of vitamin E and proline by stirring while stirring at room temperature or heating, By distilling off the organic solvent and drying, it was found that the powder had high vitamin E content and good fluidity, and the present invention was completed.
すなわち本発明は、
(1)有機溶媒中で、ビタミンEとプロリンを攪拌することによって複合体を形成し、有機溶媒を留去、乾燥させて得られるビタミンE含有粉末、
(2)ビタミンEに対するプロリンの重量比が、1:0.27〜1:0.67であることを特徴とする(1)記載のビタミンE含有粉末、
(3)有機溶媒中で、ビタミンEとプロリンを攪拌することによって複合体を形成し、有機溶媒を留去、乾燥させることを特徴とするビタミンE含有粉末の製造方法、
(4)ビタミンEに対するプロリンの重量比が、1:0.27〜1:0.67であることを特徴とする(3)記載のビタミンE含有粉末の製造方法
に関するものである。
That is, the present invention
(1) A vitamin E-containing powder obtained by forming a complex by stirring vitamin E and proline in an organic solvent, distilling off the organic solvent and drying;
(2) The vitamin E-containing powder according to (1), wherein the weight ratio of proline to vitamin E is 1: 0.27 to 1: 0.67,
(3) A method for producing a vitamin E-containing powder characterized in that a complex is formed by stirring vitamin E and proline in an organic solvent, and the organic solvent is distilled off and dried.
(4) The weight ratio of proline to vitamin E is 1: 0.27 to 1: 0.67, and relates to the method for producing a vitamin E-containing powder according to (3).
本発明者が、ビタミンEの粉末化にあたって、ビタミンEと混合させる物質として、食品添加物の一種から選択すべく検討したところ、アミノ酸が好ましいと判断した。 When the present inventor studied to select one kind of food additive as a substance to be mixed with vitamin E in powdering vitamin E, it was determined that an amino acid is preferable.
しかし、アミノ酸も多種あるところいろいろ実験を重ねた結果、プロリンのみが粉末化可能であることを見出し、本発明を完成させた。 However, as a result of repeating various experiments in a variety of amino acids, it was found that only proline can be powdered, and the present invention was completed.
本発明で用いるビタミンEは、大豆及び菜種などの種子あるいはパーム油脂から抽出精製された天然ビタミンE、あるいは合成ビタミンEであり、d−α−トコフェロール、d−β−トコフェロール、d−γ−トコフェロール、d−δ−トコフェロール、d−α−トコトリエノール、d−β−トコトリエノール、d−γ−トコトリエノール、d−δ−トコトリエノール及びdl−α−トコフェロールの内1または2以上の混合物である。該ビタミンEは、常温で油状であり、さらには脂溶性で粘性が極めて高い。 Vitamin E used in the present invention is natural vitamin E extracted from seeds such as soybean and rapeseed or palm oil or synthetic vitamin E, and is d-α-tocopherol, d-β-tocopherol, d-γ-tocopherol. , D-δ-tocopherol, d-α-tocotrienol, d-β-tocotrienol, d-γ-tocotrienol, d-δ-tocotrienol and dl-α-tocopherol. The vitamin E is oily at room temperature, and is fat-soluble and extremely viscous.
本発明で用いるプロリンは、人体を形成するタンパク質の構成成分である20種類のアミノ酸の一種であり、皮膚などを構成するコラーゲンの主要成分である。一般的な性質は、複素環を有した構造であり、弱い甘味を呈し、脂肪分解酵素リパーゼの活性化、コラーゲン合成促進活性及び表皮細胞増殖促進活性などの生理活性を示し、さらには即効性のエネルギー源となる。 Proline used in the present invention is one of 20 amino acids that are constituents of proteins that form the human body, and is a major component of collagen that constitutes the skin and the like. A general property is a structure having a heterocyclic ring, which exhibits weak sweetness, exhibits physiological activities such as lipolytic enzyme lipase activation, collagen synthesis promoting activity and epidermal cell proliferation promoting activity, and also has an immediate effect. It becomes an energy source.
ビタミンEとプロリンの比率は、重量換算でビタミンE:プロリン=1:0.1〜1:10であることが好ましく、より好ましくは、ビタミンE:プロリン=1:0.27〜1:0.67である。本発明は、ビタミンE含量が高く、且つ、流動性の良い粉末を得ることが目的であり、重量換算でビタミンEが1に対してプロリンが0.27よりも低い場合には、粉体の流動性が悪くなり、重量換算でビタミンEが1に対してプロリンが0.67よりも高い場合には、ビタミンEの含量が低下してくる。 The ratio of vitamin E to proline is preferably vitamin E: proline = 1: 0.1 to 1:10 in terms of weight, more preferably vitamin E: proline = 1: 0.27 to 1: 0. 67. The object of the present invention is to obtain a powder having a high vitamin E content and good fluidity. When vitamin E is 1 and proline is lower than 0.27 in terms of weight, When the fluidity is deteriorated and vitamin E is 1 in weight conversion and proline is higher than 0.67, the content of vitamin E decreases.
本発明で用いる有機溶媒は、メタノール、エタノール、プロパノール及びブタノール等のアルコール類であり、ビタミンEとプロリンを溶解させるものであるならば何れを用いてもかまわないが、食品への用途を考えると、エタノールを用いることが好ましい。 The organic solvent used in the present invention is alcohols such as methanol, ethanol, propanol and butanol, and any of them can be used as long as it dissolves vitamin E and proline. It is preferable to use ethanol.
エタノール量は、ビタミンEとプロリンの仕込み量に対して10倍量(V/W)以上であることが好ましい。 The amount of ethanol is preferably 10 times the amount (V / W) or more of the amount of vitamin E and proline charged.
本発明のビタミンE含量が高く、且つ、流動性の良い粉末は、以下に述べる方法で製造ができるが、これに限定されるものではない。ビタミンE、プロリン及びエタノールを、加温あるいは加熱装置が取り付けられているタンクに所定量を入れ、加温しながら所定時間攪拌した後、エタノールを留去し、次いで乾燥させる。エタノールの留去は、蒸留あるいは減圧蒸留装置などの一般的な装置を用いて行い、粉末の乾燥は、噴霧乾燥、ドラム乾燥、ベルト乾燥あるいは凍結乾燥機などの一般的な装置を用いて行うことができる。 The powder having high vitamin E content and good fluidity of the present invention can be produced by the method described below, but is not limited thereto. A predetermined amount of vitamin E, proline and ethanol are put into a tank equipped with a heating or heating device and stirred for a predetermined time while heating, and then ethanol is distilled off and then dried. Evaporation of ethanol should be performed using a general apparatus such as distillation or vacuum distillation apparatus, and powder drying should be performed using a general apparatus such as spray drying, drum drying, belt drying or freeze dryer. Can do.
かくして得られる粉末は、ビタミンE含量が高く、粉体の流動性が良い。この粉末は、ビタミンEが心筋梗塞のような冠状動脈疾患などの一次予防、前立腺癌の予防、さらにはアルツハイマーの認識機能の衰えの抑制に対して有効であることから、その生理的機能を期待した使用方法に採用できる。 The powder thus obtained has a high vitamin E content and good powder flowability. This powder is expected to have physiological functions because vitamin E is effective for primary prevention of coronary artery disease such as myocardial infarction, prevention of prostate cancer, and suppression of decline in Alzheimer's cognitive function. It can be adopted for the usage method.
本発明によって、ビタミンE含量が高く、且つ、流動性の良い粉末を作ることができ、医薬品及び食品の製造に適した粉末にすることができる。 According to the present invention, a powder having a high vitamin E content and good fluidity can be produced, and a powder suitable for production of pharmaceuticals and foods can be obtained.
以下に本発明の実施例及び比較例を挙げて、より詳細に説明するが、本発明はそれらに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples, but the present invention is not limited thereto.
表1の配合に準じ、ビタミンE(商品名:d−α−トコフェロール タマ生化学(株)製)5g、プロリン(商品名:L(−)−プロリン 和光純薬工業(株)製)5g、エタノール180mlをナス型フラスコに量りとり、75℃で3時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を10g得た。 According to the composition in Table 1, 5 g of vitamin E (trade name: d-α-tocopherol manufactured by Tama Seikagaku Co., Ltd.), 5 g of proline (trade name: L (−)-proline, manufactured by Wako Pure Chemical Industries, Ltd.), 180 ml of ethanol was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure, followed by drying under reduced pressure to obtain 10 g of white to light yellow powder.
本実施例は、ビタミンEとプロリンの比が1:1であり、ビタミンEの含量が50%であった。 In this example, the ratio of vitamin E to proline was 1: 1, and the content of vitamin E was 50%.
表1の配合に準じ、ビタミンE(商品名:d−α−トコフェロール タマ生化学(株)製)6g、プロリン(商品名:L(−)−プロリン 和光純薬工業(株)製)4g、エタノール150mlをナス型フラスコに量りとり、75℃で3時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を10g得た。 According to the composition of Table 1, vitamin E (trade name: d-α-tocopherol manufactured by Tama Biochemical Co., Ltd.) 6 g, proline (trade name: L (−)-proline manufactured by Wako Pure Chemical Industries, Ltd.) 4 g, 150 ml of ethanol was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure, followed by drying under reduced pressure to obtain 10 g of white to light yellow powder.
本実施例は、ビタミンEとプロリンの比が1:0.67であり、ビタミンEの含量が60%であった。 In this example, the ratio of vitamin E to proline was 1: 0.67, and the content of vitamin E was 60%.
表1の配合に準じ、ビタミンE(商品名:d−α−トコフェロール タマ生化学(株)製)7g、プロリン(商品名:L(−)−プロリン 和光純薬工業(株)製)3g、エタノール100mlをナス型フラスコに量りとり、75℃で3時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を10g得た。 According to the composition of Table 1, vitamin E (trade name: d-α-tocopherol manufactured by Tama Biochemical Co., Ltd.) 7 g, proline (trade name: L (−)-proline manufactured by Wako Pure Chemical Industries, Ltd.) 3 g, 100 ml of ethanol was weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Subsequently, ethanol was distilled off under reduced pressure, followed by drying under reduced pressure to obtain 10 g of white to light yellow powder.
本実施例は、ビタミンEとプロリンの比が1:0.43であり、ビタミンEの含量が70%であった。 In this example, the ratio of vitamin E to proline was 1: 0.43, and the content of vitamin E was 70%.
表1の配合に準じ、ビタミンE(商品名:d−α−トコフェロール タマ生化学(株)製)7.8g、プロリン(商品名:L(−)−プロリン 和光純薬工業(株)製)2.2g、エタノール100mlをナス型フラスコに量りとり、75℃で3時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を10g得た(図1)。 7.8 g of vitamin E (trade name: d-α-tocopherol Tama Seikagaku Co., Ltd.), proline (trade name: L (-)-proline, manufactured by Wako Pure Chemical Industries, Ltd.) 2.2 g and 100 ml of ethanol were weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Next, ethanol was distilled off under reduced pressure and then dried under reduced pressure to obtain 10 g of white to light yellow powder (FIG. 1).
本実施例は、ビタミンEとプロリンの比が1:0.28であり、ビタミンEの含量が78%であった。 In this example, the ratio of vitamin E to proline was 1: 0.28, and the content of vitamin E was 78%.
[比較例1]
表1の配合に準じ、ビタミンE(商品名:d−α−トコフェロール タマ生化学(株)製)9.1g、プロリン(商品名:L(−)−プロリン 和光純薬工業(株)製)0.9g、エタノール50mlをナス型フラスコに量りとり、75℃で3時間加熱した。次いで、エタノールを減圧留去した後、減圧乾燥させると、白色から淡黄色の粉末を10g得たが、粉末の流動性は良くなかった。
[Comparative Example 1]
According to the composition of Table 1, 9.1 g of vitamin E (trade name: d-α-tocopherol manufactured by Tama Seikagaku Co., Ltd.), proline (trade name: L (−)-proline, manufactured by Wako Pure Chemical Industries, Ltd.) 0.9 g and 50 ml of ethanol were weighed into an eggplant type flask and heated at 75 ° C. for 3 hours. Next, ethanol was distilled off under reduced pressure, and then dried under reduced pressure to obtain 10 g of white to light yellow powder, but the fluidity of the powder was not good.
本比較例は、ビタミンEとプロリンの比が1:0.099であり、ビタミンEの含量が91%であった。 In this comparative example, the ratio of vitamin E and proline was 1: 0.099, and the content of vitamin E was 91%.
[比較例2]
表2の配合に準じ、プロリンを同じアミノ酸であるグリシン(商品名:グリシン 和光純薬工業(株)製)3gに代えた以外は実施例3と同様の操作をしたが、粉末にはならなかった。
[Comparative Example 2]
According to the composition in Table 2, the same operation as in Example 3 was performed except that proline was replaced with 3 g of glycine (trade name: glycine, manufactured by Wako Pure Chemical Industries, Ltd.), which is the same amino acid. It was.
[比較例3〜16]
表2の配合に準じ、プロリンを同じアミノ酸であるL−アラニン(商品名:L−アラニン 和光純薬工業(株)製)3g(比較例3)、あるいは4−アミノ酪酸(商品名:4−アミノ酪産 和光純薬工業(株)製)3g(比較例4)、あるいはL−セリン(商品名:L−セリン 和光純薬工業(株)製)3g(比較例5)、あるいはL−バリン(商品名:L−バリン 和光純薬工業(株)製)3g(比較例6)、あるいはL−スレオニン(商品名:L−スレオニン 和光純薬工業(株)製)3g(比較例7)、あるいはL−システイン(商品名:L−システイン 和光純薬工業(株)製)3g(比較例8)、あるいはL−ロイシン(商品名:L−ロイシン 和光純薬工業(株)製)3g(比較例9)、あるいはL−アスパラギン(商品名:L−アスパラギン 和光純薬工業(株)製)3g(比較例10)、あるいはL−リシン(商品名:L−リシン 和光純薬工業(株)製)3g(比較例11)、あるいはL−グルタミン酸(商品名:L−グルタミン酸 和光純薬工業(株)製)3g(比較例12)、あるいはL−ヒスチジン(商品名:L−ヒスチジン 和光純薬工業(株)製)3g(比較例13)、あるいはL(−)−フェニルアラニン(商品名:L(−)−フェニルアラニン 和光純薬工業(株)製)3g(比較例14)、あるいはL(+)−アルギニン(商品名:L(+)−アルギニン 和光純薬工業(株)製)3g(比較例15)、あるいはL−チロシン(商品名:L−チロシン 和光純薬工業(株)製)3g(比較例16)に代えた以外は実施例3と同様の操作をしたが、何れも粉末にはならなかった。
[Comparative Examples 3 to 16]
According to the composition of Table 2, 3 g of L-alanine (trade name: L-alanine manufactured by Wako Pure Chemical Industries, Ltd.), which is the same amino acid as proline, (comparative example 3), or 4-aminobutyric acid (trade name: 4- Aminodairy product Wako Pure Chemical Industries, Ltd. 3 g (Comparative Example 4), or L-serine (trade name: L-Serine Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 5), or L-valine (Trade name: L-valine manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 6), or L-threonine (trade name: L-threonine manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 7), Alternatively, L-cysteine (trade name: L-cysteine manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 8), or L-leucine (trade name: L-leucine manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (comparative) Example 9) or L-asparagine (trade name: L-asparagine, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 1) ) Or L-lysine (trade name: L-lysine, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 11), or L-glutamic acid (trade name: L-glutamic acid, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 12) or L-histidine (trade name: L-histidine, manufactured by Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 13), or L (-)-phenylalanine (trade name: L (-)-phenylalanine Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 14), or L (+)-Arginine (trade name: L (+)-Arginine, Wako Pure Chemical Industries, Ltd.) 3 g (Comparative Example 15), or The same operation as in Example 3 was performed except that 3 g of L-tyrosine (trade name: L-tyrosine, manufactured by Wako Pure Chemical Industries, Ltd.) (Comparative Example 16) was used, but none of the powders became powder.
[比較例17、18]
表2の配合に準じ、プロリンを同じアミノ酸であるL−トリプトファン(商品名:L−トリプトファン 和光純薬工業(株)製)4g(比較例17)、あるいはL−シスチン(商品名:L−シスチン 和光純薬工業(株)製)4g(比較例18)に代えた以外は実施例2と同様の操作をしたが、何れも粉末にはならなかった。
[Comparative Examples 17 and 18]
According to the composition of Table 2, 4 g of L-tryptophan (trade name: L-tryptophan, manufactured by Wako Pure Chemical Industries, Ltd.) which is the same amino acid as proline (Comparative Example 17), or L-cystine (trade name: L-cystine) The same operation as in Example 2 was performed except that 4 g (Comparative Example 18) was changed to 4 g (Comparative Example 18) manufactured by Wako Pure Chemical Industries, Ltd.
プロリンの代わりに、表2記載の17種類のアミノ酸を用いて、ビタミンEとの複合体を形成できるのか実験を行ったが、何れの実験でも粉末にすることができず、このことからビタミンEとプロリンは特異的に複合体を形成し、粉末になることがわかった。 An experiment was conducted to determine whether a complex with vitamin E could be formed using 17 kinds of amino acids listed in Table 2, instead of proline. And proline were found to form a complex specifically into a powder.
[実験例1]
実施例4において得られた粉末を用いて、粉末中のビタミンE含量の測定、安息角、カサ密度、タッピング密度及び融点などの物性値の測定を行った。
[Experiment 1]
Using the powder obtained in Example 4, the vitamin E content in the powder was measured, and the physical properties such as the angle of repose, the bulk density, the tapping density and the melting point were measured.
粉末に含まれるビタミンE含量の測定方法は、粉末に対して40倍量(V/W)の50vol%エタノール水と20倍量(V/W)のヘキサンを用いて分配し、ヘキサンを溶媒留去・乾燥すると粘稠な油を得るので、この油を食品添加物公定書第7版記載の方法でビタミンE含量を定量し、粉末を抽出して得られた油量に、抽出した油中のビタミンE含量を乗じて得られたビタミンE量を、抽出時に用いた粉末量で割った値を百分率で表した値が粉末中のビタミンE含量となるので、結果を表3に示した。 The method for measuring the vitamin E content contained in the powder is to use 40 volumes (V / W) of 50 vol% ethanol water and 20 volumes (V / W) of hexane for the powder. Since a viscous oil is obtained when dried and dried, the vitamin E content of this oil is quantified by the method described in the 7th edition of the Food Additives Standard, and the amount of oil obtained by extracting the powder is extracted into the extracted oil. The value obtained by multiplying the amount of vitamin E obtained by multiplying the amount of vitamin E by the amount of powder used at the time of extraction as a percentage is the vitamin E content in the powder. The results are shown in Table 3.
さらには、粉末の流動性を調べるため、ABD粉体特性測定器(筒井理化学器械(株)製)を用いて、安息角、カサ密度及びタッピング密度を測定し、結果を表3に示した。 Furthermore, in order to investigate the fluidity of the powder, the angle of repose, the bulk density, and the tapping density were measured using an ABD powder property measuring instrument (manufactured by Tsutsui Chemical Co., Ltd.), and the results are shown in Table 3.
粉末の融点は、MICRO MELTING POINT APPARATUS((株)柳本製作所製)を用いて測定し、結果を表3に示した。 The melting point of the powder was measured using MICRO MELTING POINT APPARATUS (manufactured by Yanagimoto Seisakusho Co., Ltd.), and the results are shown in Table 3.
表3の結果より、実施例4の本発明である粉末は、粉末中のビタミンE含量は78%、安息角39°、カサ密度0.44g/ml、タッピング密度0.53g/ml及び融点63〜65℃となり、ビタミンE含量が高く、且つ、流動性の良い粉末であることがわかる。 From the results of Table 3, the powder of the present invention of Example 4 has a vitamin E content of 78%, an angle of repose of 39 °, a bulk density of 0.44 g / ml, a tapping density of 0.53 g / ml, and a melting point of 63. It can be seen that the powder is ˜65 ° C., has a high vitamin E content, and has good fluidity.
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006195602A JP4029109B1 (en) | 2006-07-18 | 2006-07-18 | Complex powder of vitamin E and proline and method for producing the same |
PCT/JP2007/061686 WO2008010362A1 (en) | 2006-07-18 | 2007-06-05 | Powder of vitamin e/proline complex and method of producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006195602A JP4029109B1 (en) | 2006-07-18 | 2006-07-18 | Complex powder of vitamin E and proline and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP4029109B1 JP4029109B1 (en) | 2008-01-09 |
JP2008024603A true JP2008024603A (en) | 2008-02-07 |
Family
ID=38956697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006195602A Active JP4029109B1 (en) | 2006-07-18 | 2006-07-18 | Complex powder of vitamin E and proline and method for producing the same |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4029109B1 (en) |
WO (1) | WO2008010362A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011519886A (en) * | 2008-05-09 | 2011-07-14 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Method for producing intermediate powder formulation and final solid dosage form under application of spray coagulation process |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
WO2019128175A1 (en) | 2017-12-26 | 2019-07-04 | 上海共晶医药科技有限公司 | Cocrystal of tocopherol and proline and preparation method therefor |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58201725A (en) * | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | Composition for preventing browning |
JPS6058918A (en) * | 1983-09-12 | 1985-04-05 | Advance Res & Dev Co Ltd | Additive for medical purposes |
-
2006
- 2006-07-18 JP JP2006195602A patent/JP4029109B1/en active Active
-
2007
- 2007-06-05 WO PCT/JP2007/061686 patent/WO2008010362A1/en active Application Filing
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
JP2011519886A (en) * | 2008-05-09 | 2011-07-14 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Method for producing intermediate powder formulation and final solid dosage form under application of spray coagulation process |
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
WO2019128175A1 (en) | 2017-12-26 | 2019-07-04 | 上海共晶医药科技有限公司 | Cocrystal of tocopherol and proline and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
WO2008010362A1 (en) | 2008-01-24 |
JP4029109B1 (en) | 2008-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4029109B1 (en) | Complex powder of vitamin E and proline and method for producing the same | |
Tevatia et al. | The taurine biosynthetic pathway of microalgae | |
EA201000400A1 (en) | SOLID FATTY COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, AND METHODS FOR THEIR RECEIVING AND USE | |
WO2013129667A1 (en) | High-purity acid-form sophorolipid (sl) containing composition and process for preparing same | |
ATE500739T1 (en) | VEGETABLE FAT MIXTURE AND EDIBLE PRODUCTS CONTAINING SUCH A FAT MIXTURE | |
CN109152377A (en) | The method of composition of the preparation comprising omega-fatty acid salt and amine | |
CN104357595B (en) | Give leather fat of leather shielding ultraviolet rays function and preparation method thereof | |
CN108634097A (en) | A kind of dog grain additive with the U.S. bright hair of hair and preparation method thereof and include its dog grain | |
Borges et al. | Valorization of porcine by-products: a combined process for protein hydrolysates and hydroxyapatite production | |
Gambari et al. | Glucoraphanin increases intracellular hydrogen sulfide (H2S) levels and stimulates osteogenic differentiation in human mesenchymal stromal cell | |
CN103940654B (en) | Method and the thin-layer chromatography detection method of vitamin E is extracted from useless white bole | |
Wang et al. | 2-(1 H-Pyrrolyl) carboxylic acids as pigment precursors in garlic greening | |
Rondel et al. | Synthesis and properties of lipoamino acid–fatty acid mixtures: influence of the amphiphilic structure | |
CN109602621A (en) | A kind of skin care item and preparation method thereof containing choline gallate | |
Lee et al. | Generation of volatiles from heated enzymatic hydrolysates of perilla meal with coconut oil in Maillard reaction system | |
CN1068731A (en) | Cosmetic gel | |
BR0206640A (en) | Creamy food product and process for its preparation | |
JP2014084302A (en) | S-adenosylmethionine-containing yeast and pyrroloquinoline quinone composition | |
CN109310726B (en) | Absorption enhancer for garlic component | |
Liu et al. | Is Pulsed Electric Field (PEF) a Useful Tool for the Valorization of Solid and Liquid Sea Bass Side Streams?: Evaluation of Nutrients and Contaminants | |
Coscueta et al. | Turning Discarded Blue Shark (Prionace glauca) Skin into a Valuable Nutraceutical Resource: An Enzymatic Collagen Hydrolysate | |
Orodu et al. | Extraction And Gcms Analysis Of Oil From Red Cocoyam Peel (Colocasia esculenta) | |
TWI578917B (en) | Use of aquatic gelatin in forming highly emulsified fats | |
Shen et al. | Isolation and characterisation of zinc-chelating peptides from tilapia (Oreochromis niloticus) protein hydrolysate | |
Dorm et al. | Synthesis of a cysteine Diels–Alder-based polymer by simultaneous double-click chemistry and its cyto-genotoxicity evaluation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071002 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071015 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101019 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4029109 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101019 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111019 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111019 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121019 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131019 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |